NASHVILLE - Directors of Provectus Biopharmaceuticals misrepresented the status of its primary product, a melanoma drug, and the share price fell from $5.22 to 73 cents after the truth came out, shareholders claim in a federal derivative complaint.
Categories / Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026